RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Phase II/III Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease
Latest Information Update: 01 Aug 2024
At a glance
- Drugs Fenretinide (Primary)
- Indications COVID 2019 infections; Respiratory insufficiency; SARS-CoV-2 acute respiratory disease
- Focus Registrational; Therapeutic Use
- Acronyms RESOLUTION
- Sponsors Laurent Pharmaceuticals
Most Recent Events
- 30 Jul 2024 Status changed from active, no longer recruiting to completed.
- 11 Mar 2024 Planned End Date changed from 30 Dec 2023 to 30 May 2024.
- 21 Nov 2023 Status changed from recruiting to active, no longer recruiting.